← Back to Search

Checkpoint Inhibitor

DCC-3014 + Avelumab for Sarcoma

Phase 1
Waitlist Available
Led By Sandra D'Angelo, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing a new drug combo to see if it's safe for people with advanced sarcomas.

Who is the study for?
Adults (18+) with advanced or metastatic sarcomas, specifically undifferentiated pleomorphic, myxofibrosarcoma, leiomyosarcoma, or dedifferentiated liposarcoma. Participants must have had at least one prior systemic therapy and show measurable disease progression. They should be in good health otherwise and willing to use effective contraception.Check my eligibility
What is being tested?
The trial is testing the combination of DCC-3014 with Avelumab to determine the safest dose for treating advanced sarcomas without causing severe side effects. The study involves participants who meet specific criteria related to their cancer type and previous treatments.See study design
What are the potential side effects?
While not explicitly listed in the provided information, common side effects for drugs like DCC-3014 and Avelumab may include fatigue, infusion reactions, immune-related conditions such as thyroid disorders or pneumonitis, skin rash, nausea, and increased risk of infections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum tolerated dose
Overall Response Rate

Side effects data

From 2020 Phase 2 trial • 19 Patients • NCT03006848
17%
Musculoskeletal and connective tissue disorders
11%
Injury, poisoning and procedural complications
6%
Cardiac disorders
6%
Immune system disorders
6%
Investigations
6%
Infections and infestations
6%
Metabolism and nutrition disorders
6%
Nervous system disorders
6%
General disorders and administration site conditions
6%
Gastrointestinal disorders
6%
Endocrine disorders
6%
Respiratory, thoracic and mediastinal disorders
6%
Blood and lymphatic system disorders
6%
Neoplasms benign, malignant and unspecified
6%
Renal and urinary disorders
6%
Skin and subcutaneous tissue disorders
100%
80%
60%
40%
20%
0%
Study treatment Arm
Avelumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: Advanced High-grade SarcomaExperimental Treatment2 Interventions
Dose Escalation: Up to 18 pts with locally advanced or metastatic high-grade sarcomas Dose Expansion: 10 pts per each diagnosis - undifferentiated pleomorphic sarcoma or myxofibrosarcoma, Leiomyosarcoma, Dedifferentiated liposarcoma
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Avelumab
2018
Completed Phase 2
~2450

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,588 Total Patients Enrolled
70 Trials studying Sarcoma
13,735 Patients Enrolled for Sarcoma
ENABLE MEDICINEUNKNOWN
Sandra D'Angelo, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
185 Total Patients Enrolled
3 Trials studying Sarcoma
143 Patients Enrolled for Sarcoma

Media Library

Avelumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04242238 — Phase 1
Sarcoma Research Study Groups: Advanced High-grade Sarcoma
Sarcoma Clinical Trial 2023: Avelumab Highlights & Side Effects. Trial Name: NCT04242238 — Phase 1
Avelumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04242238 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total enrollment capacity for this medical research?

"At present, this trial is not looking for participants. The original posting was on January 22nd 2020 with the last update made in October 26th 2022. If you are curious about other studies focussing on sarcoma and DCC-3014 specifically, there are currently 478 and 111 trials recruiting patients respectively."

Answered by AI

Are new participants being accepted to this research project?

"Unfortunately, this medical trial is not presently enlisting participants. Initially posted on January 22nd 2020 and adjusted as of October 26th 2022 - if you seek other clinical trials, there are 478 studies actively recruiting sarcoma patients and 111 for DCC-3014 looking for volunteers."

Answered by AI

Has DCC-3014 been evaluated in past studies?

"Currently, 111 trials for DCC-3014 are currently in progress, with 10 of them being Phase 3. These studies have been established across 3678 centres; the majority being located in Barcelona and South dakota."

Answered by AI

Has the FDA officially sanctioned DCC-3014?

"The team at Power gave DCC-3014 a score of 1 due to its Phase 1 status, indicating there is minimal evidence supporting safety and efficacy."

Answered by AI

Has a similar research effort ever been undertaken before?

"EMD Serono Research & Development Institute, Inc. kickstarted the exploration of DCC-3014 back in 2014 by running a 204 patient trial and subsequently gained approval for Phase 2 clinical trials. As it stands today, there are 111 live studies being conducted worldwide across 1024 cities spread over 52 countries."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
2020. "Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04242238.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top